Kazia Therapeutics (NASDAQ:KZIA) Stock Price Up 8.1%

Shares of Kazia Therapeutics Limited (NASDAQ:KZIA) rose 8.1% during trading on Monday . The stock traded as high as $0.44 and last traded at $0.42. Approximately 1,220,200 shares traded hands during trading, a decline of 77% from the average daily volume of 5,214,690 shares. The stock had previously closed at $0.39.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price objective on shares of Kazia Therapeutics in a research report on Friday, July 12th.

Kazia Therapeutics Stock Performance

The firm has a 50 day simple moving average of $0.40 and a two-hundred day simple moving average of $0.33.

Institutional Investors Weigh In On Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. Armistice Capital LLC acquired a new stake in Kazia Therapeutics Limited (NASDAQ:KZIA) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 2,475,555 shares of the company’s stock, valued at approximately $1,088,000. Armistice Capital LLC owned 15.15% of Kazia Therapeutics as of its most recent filing with the SEC. 30.89% of the stock is currently owned by institutional investors.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.